Seoulin BioscienceLtd Past Earnings Performance
Past criteria checks 0/6
Seoulin BioscienceLtd's earnings have been declining at an average annual rate of -13.4%, while the Biotechs industry saw earnings growing at 3.8% annually. Revenues have been growing at an average rate of 12% per year.
Key information
-13.4%
Earnings growth rate
-13.2%
EPS growth rate
| Biotechs Industry Growth | 11.7% |
| Revenue growth rate | 12.0% |
| Return on equity | -3.4% |
| Net Margin | -0.7% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Seoulin Bioscience Co.,Ltd. (KOSDAQ:038070) Is An Attractive Dividend Stock - Here's Why
May 03
Should Weakness in Seoulin Bioscience Co.,Ltd.'s (KOSDAQ:038070) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?
Mar 13Introducing Seoulin BioscienceLtd (KOSDAQ:038070), A Stock That Climbed 54% In The Last Year
Feb 15Is Seoulin Bioscience Co.,Ltd. (KOSDAQ:038070) A Great Dividend Stock?
Jan 20
Three Days Left Until Seoulin Bioscience Co.,Ltd. (KOSDAQ:038070) Trades Ex-Dividend
Dec 25Is Seoulin Bioscience Co.,Ltd.'s (KOSDAQ:038070) Recent Stock Performance Influenced By Its Fundamentals In Any Way?
Dec 06Revenue & Expenses Breakdown
How Seoulin BioscienceLtd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 84,514 | -591 | 14,713 | 818 |
| 31 Mar 24 | 85,821 | -1,357 | 14,350 | 738 |
| 31 Dec 23 | 89,569 | -118 | 14,954 | 785 |
| 30 Sep 23 | 83,878 | 3,307 | 14,276 | 890 |
| 30 Jun 23 | 86,538 | 3,945 | 14,311 | 906 |
| 31 Mar 23 | 100,637 | 9,869 | 13,351 | 904 |
| 31 Dec 22 | 104,708 | 10,129 | 12,928 | 870 |
| 30 Sep 22 | 103,570 | 8,765 | 12,983 | 753 |
| 30 Jun 22 | 103,586 | 20,650 | 12,460 | 742 |
| 31 Mar 22 | 89,475 | 16,315 | 12,071 | 755 |
| 31 Dec 21 | 80,539 | 15,700 | 11,172 | 787 |
| 30 Sep 21 | 80,219 | 17,670 | 10,199 | 809 |
| 30 Jun 21 | 75,105 | 5,890 | 9,850 | 915 |
| 31 Mar 21 | 67,689 | 5,353 | 9,603 | 970 |
| 31 Dec 20 | 65,085 | 4,893 | 9,522 | 998 |
| 30 Sep 20 | 62,520 | 4,251 | 9,788 | 1,077 |
| 30 Jun 20 | 58,349 | 4,068 | 9,784 | 955 |
| 31 Mar 20 | 57,042 | 9,437 | 9,989 | 985 |
| 31 Dec 19 | 54,410 | 8,884 | 9,861 | 955 |
| 30 Sep 19 | 50,756 | 8,590 | 10,172 | 1,135 |
| 30 Jun 19 | 51,700 | 8,346 | 10,270 | 1,184 |
| 31 Mar 19 | 51,231 | 2,640 | 10,113 | 1,183 |
| 31 Dec 18 | 49,877 | 2,625 | 10,028 | 1,190 |
| 30 Sep 18 | 47,444 | 2,314 | 9,973 | 1,126 |
| 30 Jun 18 | 43,512 | 1,714 | 9,648 | 1,085 |
| 31 Mar 18 | 42,317 | 1,540 | 9,659 | 983 |
| 31 Dec 17 | 42,619 | 2,061 | 9,495 | 998 |
| 30 Sep 17 | 44,437 | 3,008 | 8,774 | 857 |
| 30 Jun 17 | 44,937 | 3,007 | 9,272 | 679 |
| 31 Mar 17 | 46,698 | 4,710 | 9,266 | 668 |
| 31 Dec 16 | 44,889 | 4,073 | 8,768 | 795 |
| 30 Sep 16 | 44,314 | 3,599 | 9,033 | 661 |
| 30 Jun 16 | 43,481 | 3,230 | 8,915 | 661 |
| 31 Mar 16 | 42,044 | 1,772 | 8,368 | 644 |
| 31 Dec 15 | 41,628 | 1,825 | 8,242 | 566 |
| 30 Sep 15 | 41,538 | 1,952 | 7,871 | 591 |
| 30 Jun 15 | 39,682 | 2,257 | 7,769 | 591 |
| 31 Mar 15 | 37,754 | 2,093 | 8,078 | 630 |
| 31 Dec 14 | 37,662 | 2,668 | 8,147 | 744 |
| 30 Sep 14 | 34,861 | 2,243 | 8,290 | 945 |
| 30 Jun 14 | 36,059 | 3,224 | 7,246 | 945 |
| 31 Mar 14 | 39,501 | 3,861 | 5,354 | 913 |
| 31 Dec 13 | 42,196 | 4,160 | 5,634 | 1,046 |
Quality Earnings: A038070 is currently unprofitable.
Growing Profit Margin: A038070 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A038070 is unprofitable, and losses have increased over the past 5 years at a rate of 13.4% per year.
Accelerating Growth: Unable to compare A038070's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A038070 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (5.8%).
Return on Equity
High ROE: A038070 has a negative Return on Equity (-3.39%), as it is currently unprofitable.